Klencke Barbara
Transaction: 05/20/2026
BUY
Change
+67,000
Price
$0.99
Filing
05/22/2026
Type
BUY
TScan Therapeutics, Inc.
TCRX • Biotechnology
$0.39
▲ +0.02 (+5.55%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$48.80M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.76Healthy liquidity · 8.15Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:31 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.39
Change5.55%
Shares Out129.95M
Market Cap$48.80M
Enterprise Value$-51.36M
52W Range0.72 - 2.57
Beta1.07
P/E-0.41
P/S8.05
P/B0.71
P/FCF-0.41
EV/Sales-8.48
Price$0.39
Change5.55%
Shares Out129.95M
Market Cap$48.80M
Enterprise Value$-51.36M
52W Range0.72 - 2.57
Beta1.07
P/E-0.41
P/S8.05
P/B0.71
P/FCF-0.41
EV/Sales-8.48
EV/EBITDA0.45
EV/FCF0.43
Earnings Yield-241.23%
FCF Yield-242.72%
Dividend Yield0.00%
Gross Margin72.24%
Oper. Margin-13.15%
Profit Margin-12.57%
Debt/Eq0.76
Current Ratio8.15
Quick Ratio8.15
Target$1.00
Target Upside155.43%
Target Median$1.00
Target Range1.00 - 1.00
Volume297.61K
Avg Volume829.65K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
35
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
71/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
57/100
Why this score▼
Manageable debt level · 0.76Healthy liquidity · 8.15Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-09-04
81/100
Bullish
Bullish
5
Hold
3
Bearish
0
Price Target
2026-08-14
Low
$3.00
Mean
$7.50
Median
$7.50
High
$12.00
Insider Transactions
Recent executive and insider activity
Dorton Katina
Transaction: 05/20/2026
BUY
Change
+67,000
Price
$0.99
Filing
05/22/2026
Type
BUY
Gruia Gabriela
Transaction: 05/20/2026
BUY
Change
+67,000
Price
$0.99
Filing
05/22/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Klencke Barbara | BUY | +67,000 | $0.99 | 05/20/2026 | 05/22/2026 |
| Dorton Katina | BUY | +67,000 | $0.99 | 05/20/2026 | 05/22/2026 |
| Gruia Gabriela | BUY | +67,000 | $0.99 | 05/20/2026 | 05/22/2026 |
| Nicholson Garry A | BUY | +67,000 | $0.99 | 05/20/2026 | 05/22/2026 |
| Woods Keith | BUY | +67,000 | $0.99 | 05/20/2026 | 05/22/2026 |
| BAKER BROS. ADVISORS LP | BUY | +67,000 | $0.99 | 05/20/2026 | 05/22/2026 |
| ZDRAVESKI ZORAN | BUY | +350,000 | $1.12 | 01/20/2026 | 01/22/2026 |
| Louis Chrystal | BUY | +420,000 | $1.12 | 01/20/2026 | 01/22/2026 |
| Dworak Leiden | BUY | +100,000 | $1.12 | 01/20/2026 | 01/22/2026 |
| MacBeath Gavin | BUY | +1,165,000 | $1.12 | 01/20/2026 | 01/22/2026 |
| Amello Jason | BUY | +350,000 | $1.12 | 01/20/2026 | 01/22/2026 |
| Lynx1 Capital Management LP | BUY | +6,232 | $0.90 | 12/23/2025 | 12/23/2025 |
| Lynx1 Capital Management LP | BUY | +75,500 | $0.90 | 12/22/2025 | 12/23/2025 |
| Lynx1 Capital Management LP | BUY | +80,069 | $0.90 | 12/19/2025 | 12/23/2025 |
| Dworak Leiden | OTHER | +37,500 | $2.90 | 08/14/2025 | 08/22/2025 |
| Gruia Gabriela | BUY | +67,000 | $1.45 | 06/30/2025 | 07/02/2025 |
| Dorton Katina | BUY | +67,000 | $1.45 | 06/30/2025 | 07/02/2025 |
| Woods Keith | BUY | +67,000 | $1.45 | 06/30/2025 | 07/02/2025 |
| Nicholson Garry A | BUY | +67,000 | $1.45 | 06/30/2025 | 07/02/2025 |
| Klencke Barbara | BUY | +67,000 | $1.45 | 06/30/2025 | 07/02/2025 |